| 摘要 |
Compounds having a chemical formula selected from the group consisting of formulae (I), (II) and (III) or a pharmaceutically acceptable salt thereof, wherein: A is independent of any other group and is selected from the group consisting of -CH2- and -CH2-CH2-; B is independent of any other group and is selected from the group consisting of -(CH2)n-, -(CH2O)n-, -(CH2S)n-, -(OCH2)n-, -(SCH2)n-, -(CH=CH)n-, -(CC)n-, -CON(R6)-, -N(R6)CO-, -O-, -S- and -N(R6)-; R2 is independent of any other R group and is selected from the group consisting of -H, -COOH, -COR5, -CONR5R6, -(CH2)n-W-(CH2)m-Z-R5, -(CH2)n-W-R5, -Z-R5, C1-C10 alkyl, alkenyl and substituted aryl; R3 is independent of any other R group and is selected from the group consisting of -H, -COOH, -COR5, -CONR5R6, -(CH2)n-W-(CH2)m-Z-R5, -(CH2)n-W-R5, -Z-R5, C1-C10 alkyl, alkenyl and substituted aryl; which inhibit the activity of phospholipase enzymes, particularly cytosolic phospholipase A2. Pharmaceutical compositions comprising such compounds and methods of treatment using such compositions are also disclosed. |
